AIV
65
-2
DTE
56
-3
STT
42
-6
XEL
60
-5
ADT
37
10
IPG
36
-4
GS
50
-15
MO
39
-3
PX
48
-2
MUR
39
-4
XRAY
40
2
CCI
39
3
MCK
42
-8
AN
41
-5
MMM
32
-5
HES
49
-7
DOV
49
-3
APH
43
-3
CNX
50
-3
EMR
47
-3
AIV
65
-2
DTE
56
-3
STT
42
-6
XEL
60
-5
ADT
37
10
IPG
36
-4
GS
50
-15
MO
39
-3
PX
48
-2
MUR
39
-4
XRAY
40
2
CCI
39
3
MCK
42
-8
AN
41
-5
MMM
32
-5
HES
49
-7
DOV
49
-3
APH
43
-3
CNX
50
-3
EMR
47
-3
Financhill
Back

Stoke Therapeutics Quote, Financials, Valuation and Earnings

Potential crash warning signs flashing again on my charts

Here's my #1 indicator to try out now.
Sell
45

STOK
Stoke Therapeutics

Last Price:
14.69
Seasonality Move:
-14.87%

7 Day Trial

ALL ACCESS PASS

$ 7

The Biggest Financial Event of 2024?

Click here to find out.

Stoke Therapeutics Price Quote

$14.69
+0.01 (+-3.04%)
(Updated: September 7, 2024 at 6:57 AM ET)

Stoke Therapeutics Key Stats

Sell
45
Stoke Therapeutics (STOK) is a Sell
Day range:
$14.16 - $15.31
52-week range:
$3.35 - $17.58
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
46.31
P/B ratio:
3.18%
Volume:
226K
Avg. volume:
412.3K
1-year change:
176.98%
Market cap:
$772.9M
Revenue:
$8.8M
EPS:
$-2.18

How Much Does Stoke Therapeutics Make?

Is Stoke Therapeutics Growing As A Company?

Data Unavailable

Stoke Therapeutics Stock Price Performance

What Is Stoke Therapeutics 52-Week High & Low?

Stoke Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Stoke Therapeutics?

Is Stoke Therapeutics Cash Flow Positive?

  • What Is STOK Cash Flow From Operations?
    Cash flow from operations (TTM) is -$80M
  • What Is Stoke Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $130.3M
  • What Is Stoke Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$48.9M

Stoke Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    STOK return on invested capital is -57.17%
  • What Is Stoke Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -41.83%
  • What Is STOK Return On Equity?
    ROE is a measure of profitability and is -57.17%

Stoke Therapeutics Earnings Date & Stock Price

Stoke Therapeutics Competitors

Stoke Therapeutics Dividend Yield

Stoke Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 18.58%
Revenue: 0% 41.57%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 22.14
Upside from Last Price: 50.84%

Major Shareholders

  • How many STOK shares are owned by institutional investors?
    83.3M STOK shares are owned by institutional investors
  • How many STOK shares are owned by insiders?
    510.6K STOK shares are owned by insiders